Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Short Interest Update

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) was the recipient of a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 502,100 shares, a growth of 8.2% from the November 30th total of 463,900 shares. Approximately 3.5% of the shares of the company are short sold. Based on an average daily volume of 124,000 shares, the days-to-cover ratio is currently 4.0 days.

Acurx Pharmaceuticals Stock Down 4.6 %

Shares of ACXP opened at $0.85 on Tuesday. The business’s 50-day moving average price is $1.36 and its 200-day moving average price is $1.86. Acurx Pharmaceuticals has a twelve month low of $0.72 and a twelve month high of $5.28. The stock has a market cap of $14.41 million, a PE ratio of -0.78 and a beta of -1.86.

Acurx Pharmaceuticals (NASDAQ:ACXP) last posted its earnings results on Tuesday, November 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.06. During the same quarter in the previous year, the firm earned ($0.24) earnings per share. Analysts expect that Acurx Pharmaceuticals will post -0.89 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Acurx Pharmaceuticals

A hedge fund recently raised its stake in Acurx Pharmaceuticals stock. Geode Capital Management LLC grew its holdings in shares of Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) by 12.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 146,500 shares of the company’s stock after acquiring an additional 16,485 shares during the quarter. Geode Capital Management LLC owned about 0.90% of Acurx Pharmaceuticals worth $278,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 11.53% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of Acurx Pharmaceuticals in a report on Tuesday, December 10th.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.